Modern Retina
@ModernRetina
Followers
3K
Following
472
Media
8K
Statuses
12K
The leading source for #Retina. We cover AMD, DME, diabetic retinopathy, uveitis, and more. Follow our parent publication @OphthTimes.
Cleveland, OH
Joined April 2019
REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD:
modernretina.com
Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).
0
0
2
Patricio Schlottmann, MD, highlights 4-year extension data during EURETINA 2025:
modernretina.com
Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.
0
0
2
The US Food and Drug Administration (FDA) has granted AAvantgarde’s AAVB-039 Orphan Drug Designation (ODD) and has also received Clinical Trial Authorisation (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).
modernretina.com
Additionally, the company also received Clinical Trial Authorization (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).
0
0
2
FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa:
modernretina.com
NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).
0
2
3
AAO 2025: Imagine what can happen during this collective experience:
modernretina.com
Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.
0
0
1
In recent years, gene therapy has emerged from the shadows of theoretical potential into the spotlight of clinical reality.
modernretina.com
Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.
0
2
2
Retina roundup: September 29 to October 3:
modernretina.com
Catch up on this week's highlights in retina.
0
0
0
Intravitreal complement inhibitor treatment for GA viewed favorably by patients:
modernretina.com
Patient response focused on perceived vision-related quality of life outcomes, investigators said.
0
1
3
The US Food and Drug Administration (FDA) has granted Nacuity Pharmaceuticals’ N-acetylcysteine amide tablets (NPI-001) breakthrough therapy designation.
modernretina.com
NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).
0
0
2
AAO 2025: What the Eye Care Network's editorial advisory board members are presenting:
modernretina.com
Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.
0
0
2
ISTH0036 shows promise in treating retinal diseases:
modernretina.com
ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.
0
0
0
The European Commission (EC) has granted marketing authorization for EYLUXVI (ALT-L9), an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.
modernretina.com
Alteogen received a positive CHMP opinion for EYLUXVI in July 2025.
0
0
2
STAAR and Broadwood clash over proposed Alcon merger:
modernretina.com
Broadwood Partners, who is against the merger, holds approximately 27.5% of the outstanding common stock of STAAR, making them the largest outside stockholder of STAAR.
0
0
0
A recent conference celebrated the creation of the first prototype of the spectral optical coherence tomography (SOCT) instrument.
modernretina.com
Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.
0
0
3
Navigating the maze: Establishing novel endpoints for IRD trials:
modernretina.com
The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.
0
0
0
Welcome to “Eichenbaum Acorns,” an editorially independent series powered by Modern Retina® and hosted by David A. Eichenbaum, MD, FASRS, partner and director of research at Retina Vitreous Associates of Florida in Tampa Bay.
modernretina.com
Behind the scenes of building impactful educational platforms in retina care
0
0
2
Navigating the maze: Establishing novel endpoints for IRD trials:
modernretina.com
The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.
0
2
5
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME:
modernretina.com
Behind the scenes of building impactful educational platforms in retina care
0
0
2
Opus Genetics recently announced the positive 3-month pediatric data from its phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5, an investigational gene therapy for Leber congenital amaurosis type 5 (LCA5).
modernretina.com
The trial results show promising for the evaluated gene therapy for the treatments of LCA, showing significant vision improvements in pediatric patients.
0
0
2
Navigating the maze: Establishing novel endpoints for IRD trials:
modernretina.com
The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.
0
0
2